CALA News and Press, Calithera Biosciences Inc. From 05/09/19

Calithera Biosciences (NASDAQ: CALA ): Q1 GAAP EPS of -$0.61 misses by $0.18 . More news on: Calithera Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on May 9, 2019-- SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company pioneering the discovery and devel...

SOUTH SAN FRANCISCO, Calif., May 03, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways, announced today that the Company ...

SOUTH SAN FRANCISCO, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced new ...

SOUTH SAN FRANCISCO, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announce...

Calithera Biosciences (CALA) Q4 2018 Earnings Conference Call March 7, 2019 16:30 ET Company Participants Jennifer McNealey - Vice President, Investor Relations and Strategy Susan Molineaux - Founder, President and Chief Executive Officer Stephanie Wong - Senior Vice President, F...

Calithera Biosciences (NASDAQ: CALA ): Q4 GAAP EPS of -$0.51 misses by $0.02 . More news on: Calithera Biosciences, Earnings news and commentary, Healthcare stocks news, , Read more ...

SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced toda...

SOUTH SAN FRANCISCO, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announce...

Here, I continue my coverage of the micro-cap oncology player AVEO Oncology ( AVEO ). In my previous piece , I discussed the issues AVEO encountered with the FDA regarding the results of the TIVO-1 trial, and how the FDA’s concerns may not be ameliorated by the available results of the...